Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Viva Gold Reports Strong Initial Assay Results for its Fall 2024 Drill Program (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Science 37 Holdings Inc SNCE

Financial Services Technology Scientific & Technical Instruments
Science 37 Holdings, Inc. is engaged in patient-centric clinical trials and in supporting novel approaches to decentralized clinical trial designs. Through its patient-centric approach, it reduces the impact of the geographic barriers associated with conventional physical clinical trial sites, enabling recruitment of virtually any patient. Its offerings lie in its configurable unified... see more

Recent & Breaking News (NDAQ:SNCE)

Science 37® Reveals a Pivotal Shift in the Clinical Trials Landscape

GlobeNewswire November 17, 2021

Science 37 Reports Quarterly Financial Results for the Period Ended September 30, 2021

GlobeNewswire November 15, 2021

Science 37 to Report Third Quarter 2021 Financial Results on November 15, 2021

GlobeNewswire November 1, 2021

Science 37® and CMIC Announce Partnership to Advance Decentralized Clinical Trials in Japan/APAC and Speed Drug Development

GlobeNewswire October 27, 2021

Science 37® and 3H Medi Solution Collaborate to Enable Decentralized Clinical Trials in Japan and Accelerate Patient Enrollment

GlobeNewswire October 27, 2021

Industry-veteran Elisa Cascade Joins Science 37 as Chief Product Officer; Chris Ceppi appointed Chief Technology Officer

GlobeNewswire October 13, 2021

Emily Rollins Appointed to Science 37® Board of Directors

GlobeNewswire October 12, 2021

Science 37, the Operating System for Agile Clinical Trials, Closes Business Combination with LifeSci Acquisition II Corp. and Will Begin Trading on Nasdaq as SNCE

GlobeNewswire October 7, 2021

LifeSci Acquisition II Corp. Announces Confidential Submission of S-4 Registration Statement Related to Proposed Business Combination

GlobeNewswire June 16, 2021

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of LifeSci Acquisition II Corp. Merger

GlobeNewswire May 12, 2021

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of LifeSci Acquisition II Corp. - LSAQ

PR Newswire May 12, 2021

Moore Kuehn Encourages MNR, LOKB, LSAQ and MFNC Investors to Contact Law Firm

GlobeNewswire May 11, 2021

SHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of LifeSci Acquisition II Corp. (Nasdaq - LSAQ)

ACCESSWIRE IA May 7, 2021

LifeSci Acquisition II Corp. Announces Pricing of $75 Million Initial Public Offering

GlobeNewswire November 20, 2020